<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Investig Clin Urol</journal-id><journal-id journal-id-type="iso-abbrev">Investig Clin Urol</journal-id><journal-id journal-id-type="publisher-id">ICU</journal-id><journal-title-group><journal-title>Investigative and Clinical Urology</journal-title></journal-title-group><issn pub-type="ppub">2466-0493</issn><issn pub-type="epub">2466-054X</issn><publisher><publisher-name>The Korean Urological Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29333515</article-id><article-id pub-id-type="pmc">5754583</article-id><article-id pub-id-type="doi">10.4111/icu.2018.59.1.49</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject><subj-group subj-group-type="subheading"><subject>Lower Urinary Tract Dysfunction</subject></subj-group></subj-group></article-categories><title-group><article-title>Changes in autonomic nervous system activity after treatment with alpha-blocker in men with lower urinary tract symptoms</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shim</surname><given-names>Kang Hee</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Tae Woo</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chung</surname><given-names>Byung Ha</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Sung Won</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Jong Kwan</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Kwangsung</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Cheon</surname><given-names>Jun</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Kyung Seop</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Hyung-Jee</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Seong</surname><given-names>Do-Hwan</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Oh</surname><given-names>Seung-June</given-names></name><xref ref-type="aff" rid="A10">10</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Sae Woong</given-names></name><xref ref-type="aff" rid="A11">11</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Ji Youl</given-names></name><xref ref-type="aff" rid="A11">11</xref></contrib><contrib contrib-type="author"><name><surname>Choo</surname><given-names>Seol Ho</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6474-9913</contrib-id><name><surname>Choi</surname><given-names>Jong Bo</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Urology, Ajou University College of Medicine, Suwon, Korea.</aff><aff id="A2"><label>2</label>Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea.</aff><aff id="A3"><label>3</label>Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</aff><aff id="A4"><label>4</label>Department of Urology, Chonbuk National University School of Medicine, Jeonju, Korea.</aff><aff id="A5"><label>5</label>Department of Urology, Chonnam National University Medical School, Gwangju, Korea.</aff><aff id="A6"><label>6</label>Department of Urology, Korea University Anam Hospital, Seoul, Korea.</aff><aff id="A7"><label>7</label>Department of Urology, Dongguk University College of Medicine, Gyeongju, Korea.</aff><aff id="A8"><label>8</label>Department of Urology, Dankook University College of Medicine, Cheonan, Korea.</aff><aff id="A9"><label>9</label>Department of Urology, Inha University College of Medicine, Incheon, Korea.</aff><aff id="A10"><label>10</label>Department of Urology, Seoul National University Hospital, Seoul, Korea.</aff><aff id="A11"><label>11</label>Department of Urology, The Catholic University of Korea College of Medicine, Seoul, Korea.</aff><author-notes><corresp>
Corresponding Author: Jong Bo Choi. Department of Urology, Ajou University College of Medicine, 164 Worldcup-ro, Yeongtong-gu, Suwon 16499, Korea. TEL: +82-31-219-5273, FAX: +82-31-219-5276, <email>urochoi@ajou.ac.kr</email></corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>15</day><month>12</month><year>2017</year></pub-date><volume>59</volume><issue>1</issue><fpage>49</fpage><lpage>54</lpage><history><date date-type="received"><day>14</day><month>6</month><year>2017</year></date><date date-type="accepted"><day>28</day><month>7</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Korean Urological Association, 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>The Korean Urological Association</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">http://creativecommons.org/licenses/by-nc/4.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Purpose</title><p>To determine changes in autonomic nervous system activity after treatment in men with lower urinary tract symptoms (LUTS), we evaluated changes in patients' symptoms, uroflowmetry, and heart rate variability (HRV) after treatment with alpha-blockers for 12 weeks.</p></sec><sec><title>Materials and Methods</title><p>Ninety-five men who had LUTS (International Prostate Symptom Score [IPSS] &#x02265;8) were included in this study. We divided them into two groups on the basis of a low frequency/high frequency (LF/HF) ratio of 1.6. After treatment with Xatral XL (Handok Inc., Korea) 10 mg for 3 months, we rechecked their IPSS, uroflowmetry, HRV and compared these with the baseline measurements.</p></sec><sec><title>Results</title><p>Fifty-four men were assigned to the low LF/HF group (group A: LF/HF &#x02264;1.6) and 41 men to the high LF/HF group (group B: LF/HF &#x0003e;1.6). At baseline and 12 weeks, none of the parameters differed significantly between the groups except for HF, which is one of the parameters of HRV. IPSS, the IPSS-voiding subscore, and the IPSS-storage subscore decreased and maximal uroflow increased significantly after 12 weeks of treatment. Whereas the baseline LF/HF ratio increased from 0.89&#x000b1;0.407 to 1.80&#x000b1;1.804 after treatment in group A, it decreased from 3.93&#x000b1;5.471 to 1.79&#x000b1;1.153 in group B.</p></sec><sec><title>Conclusions</title><p>The efficacies of Xatral XL were clear in both groups. We found that the LF/HF ratio in the two groups merged to a value of approximately 1.79 after treatment. We suggest that this could be a clue to the importance of balance in autonomic nervous system activity in men with LUTS.</p></sec></abstract><kwd-group><kwd>Autonomic nervous system</kwd><kwd>Prostate</kwd><kwd>Urination</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>Handok Inc.</institution></institution-wrap></funding-source></award-group></funding-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Male lower urinary tract symptoms (LUTS) are diverse and complicated owing to their multifactorial etiology. LUTS can be a bothersome condition that leads to anxiety and even morbidity, and treatment outcomes vary for similar reasons [<xref rid="B1" ref-type="bibr">1</xref>].</p><p>It is well known that the autonomic nervous system (ANS) regulates the micturition cycle, and central sympathetic overactivity can be associated with idiopathic overactive bladder [<xref rid="B2" ref-type="bibr">2</xref>]. Our previous studies showed a marked relationship between an imbalance in ANS activity and LUTS in men [<xref rid="B3" ref-type="bibr">3</xref><xref rid="B4" ref-type="bibr">4</xref><xref rid="B5" ref-type="bibr">5</xref>]. Therefore, we can infer that ANS activity may change after improvements in LUTS with alpha-blocker treatment or that the efficacy of treatment may differ according to ANS activity.</p><p>In this study, we used an alpha-blocker to treat male LUTS because many clinical trials have established alphablockers as a basic medicine for improving LUTS [<xref rid="B6" ref-type="bibr">6</xref>]. Alphablockers relieve bladder outlet resistance by smooth muscle relaxation of the prostate and bladder neck [<xref rid="B6" ref-type="bibr">6</xref><xref rid="B7" ref-type="bibr">7</xref>] and are a fast, effective treatment option [<xref rid="B8" ref-type="bibr">8</xref>].</p><p>Many tests are available for evaluating autonomic activity, such as the Valsalva ratio, thermoregulatory seat test, and the tilt table [<xref rid="B9" ref-type="bibr">9</xref>]. We used heart rate variability (HRV) to compare the subjects' ANS activity before and after treatment with an alpha-blocker because of its quantitative, noninvasive characteristics. HRV is a simple, reproducible test that is easy to implement in a clinical situation.</p><p>The objectives of this study were to determine changes in ANS activity after treatment with an alpha-blocker for 12 weeks and to compare differences in treatment efficacy according to the low frequency (LF)/high frequency (HF) ratio, which is a measure of the ratio of sympathetic to parasympathetic activity.</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><p>This was a subgroup analysis of a prospective, multicenter, open-label observational study reported in 2015 [<xref rid="B5" ref-type="bibr">5</xref>]. Between June 2011 and February 2013, 169 men were screened in 11 hospitals in Korea. The study protocol was reviewed by the Ajou University Institutional Review Board and approved (approval number: MED-SUR-10-338). Informed consent was obtained from all individual participants included in the study. The inclusion criteria were men aged &#x02265;50 years with a total International Prostate Symptom Score (IPSS) &#x02265;8, maximal uroflow (Qmax) rate &#x02264;15 mL/s, and a period of more than 3 months with LUTS. The exclusion criteria were allergic drug reaction to alpha-blockers, orthostatic hypotension, renal or hepatic impairment, neurogenic bladder, a history of surgery for the prostate or a pelvic organ, a serum prostate-specific antigen (PSA) value &#x02265;10 ng/mL, and history of taking any alpha-blocker for more than 4 weeks or 5-alpha-reductase inhibitors for more than 6 months before baseline. We informed the patients with a PSA level over 4 ng/mL of the need to have their PSA levels rechecked or to undergo biopsy. Subjects who were receiving or were planning to be treated with the following drugs that could affect ANS activity were excluded: alphaor beta-receptor agonists or antagonists, antihypertensive drugs, antipsychotics, anticholinergics, anxiolytics, or antidepressants. Men with accompanying disease that could influence ANS activity were also excluded, such as diabetes, hypertension, neurologic disease, cardiovascular disease, or any malignancies.</p><p>IPSS and uroflowmetry were assessed at baseline. We also measured the subjects' HRV at baseline by using an in-house system. The subjects were then divided into two groups according to their LF/HF ratio, which is one of the HRV parameters. Men with LF/HF &#x02264;1.6 were classified into group A, and the others were placed in group B. We used 1.6 as the cutoff because we had calculated the mean value of LF/HF in 118 healthy volunteers in a previous study. All subjects were treated with Xatral XL (Handok Inc., Seoul, Korea) 10 mg once daily for 12 weeks, after which we evaluated HRV, IPSS, and uroflowmetry again. We analyzed changes in total IPSS, IPSS-voiding subscore (sum of IPSS no. 1, 3, and 5), IPSS-storage subscore (sum of IPSS no. 2, 4, 6, and 7), Qmax, and LF/HF ratio after 12 weeks of treatment.</p><p>The primary endpoint of this study was the difference in change in the LF/HF ratio after treatment with Xatral XL 10 mg for 12 weeks compared to baseline. Secondary endpoints were the change in IPSS and Qmax after treatment.</p><sec><title>1. HRV measurement</title><p>We used HRV as measured with the SA-3000p (Medicore, Seoul, Korea) to evaluate the subjects' ANS activity at baseline and after 12 weeks. Before HRV measurement, all subjects received a bladder scan to confirm that their bladder contained at least 100 mL of urine. We prohibited consumption of tea or coffee and food and cigarette smoking to avoid any influence on ANS activity. We took each subject's electrocardiographic signal recording for 5 minutes while he was sitting in a comfortable positon, and then measured LF (0.04 to 0.15 Hz) and HF (0.15 to 0.40 Hz) by frequency domain analysis to calculate the LF/HF ratio.</p></sec><sec><title>2. Statistical analysis</title><p>We used IBM SPSS Statistics ver. 19.0 (IBM Co., Armonk, NY, USA) to analyze the differences in parameters with the paired t-test in each group. To evaluate differences in parameters between groups, we used independent t-tests. A p-value of &#x0003c;0.05 was considered statistically significant. All data in this study were expressed as mean&#x000b1;standard deviation.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>A total of 169 men were screened, and 95 men who finished the study protocol were included in the study (<xref ref-type="fig" rid="F1">Fig. 1</xref>) and assigned to group A (LF/HF &#x02264;1.6, n=54) or group B (LF/HF &#x0003e;1.6, n=41). Baseline characteristics did not differ significantly between the groups, except for HF, which was higher in group A (<xref ref-type="table" rid="T1">Table 1</xref>). Treatment with Xatral XL 10 mg induced statistically significant improvement in LUTS in both groups (<xref ref-type="table" rid="T2">Table 2</xref>). Total IPSS in both groups decreased after treatment compared with baseline; however, we could not detect any difference in treatment efficacy between groups. The IPSS-voiding subscore and IPSS-storage subscore decreased in the same manner as the total IPSS, and we could not find any significant differences between the groups. Qmax increased significantly after treatment with Xatral XL 10 mg for 12 weeks in both groups; however, there was no significant difference between groups.</p><p>In group A, the LF/HF ratio at baseline was 0.89&#x000b1;0.407 and it increased to 1.80&#x000b1;1.804 after 12 weeks with Xatral XL 10 mg. By contrast, the LF/HF ratio decreased from 3.93&#x000b1;5.471 to 1.79&#x000b1;1.153 in group B (p=0.01, <xref ref-type="fig" rid="F2">Fig. 2</xref>).</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The lower urinary tract is controlled by the ANS, which includes sympathetic and parasympathetic activity. The storage or voiding function of the bladder is the result of a complex series of processes by the lower urinary tract governed by ANS activity. The activation of sympathetic nerves inhibits bladder activity and stimulates the internal urethral sphincter [<xref rid="B10" ref-type="bibr">10</xref>]. The prostate is also innervated by the sympathetic and parasympathetic nervous system [<xref rid="B11" ref-type="bibr">11</xref>]. Prostate growth is associated with ANS activity. McVary et al. [<xref rid="B12" ref-type="bibr">12</xref>] showed in a study with aging rats that increased autonomic activity results in prostatic hyperplasia, and removal of the innervation induces regression of prostate weight. In another study, those authors suggested that ANS hyperactivity is related to LUTS severity and prostate size [<xref rid="B13" ref-type="bibr">13</xref>]. Thus, we can easily guess that an imbalance in ANS activity between sympathetic and parasympathetic activity could affect lower urinary tract function to induce LUTS.</p><p>HRV can affect the influence of sympathetic and vagal activity on the sinus node, and variability reflects spontaneous changes in ANS activity. HRV is a simple and reproducible index for evaluating autonomic control of the heart and autonomic dysfunction [<xref rid="B14" ref-type="bibr">14</xref>]. The clinical importance of HRV became apparent in the 1980s when HRV was identified as a strong predictor of mortality from acute myocardial infarction [<xref rid="B15" ref-type="bibr">15</xref>]. Most investigators believe that the root mean square successive difference and HF are predominantly a response to changes in parasympathetic tone, whereas standard deviation of the mean of qualified NN-interval and LF are influenced by adrenergic and cholinergic activities [<xref rid="B16" ref-type="bibr">16</xref>]. In clinical and experimental observations of autonomic tests, efferent vagal activity can be a major contributor to HF [<xref rid="B17" ref-type="bibr">17</xref>], and the LF component is considered to be a marker of sympathetic modulation by investigators [<xref rid="B18" ref-type="bibr">18</xref>]. Finally, LF and HF in HRV refer to sympathetic and parasympathetic activity, respectively, so we can say that the LF/HF ratio refers to the balance of ANS activity. Thus, the LF/HF ratio is considered to be a marker that mirrors the balance of sympathetic and parasympathetic activity, reflecting sympathetic modulation [<xref rid="B19" ref-type="bibr">19</xref>]. A high LF/HF ratio indicates that sympathetic nerve activity is higher than parasympathetic nerve activity. Although it is a good marker for ANS activity, cutoff values for identifying sympathetic hyperactivity have not been identified.</p><p>HRV has several limitations for acquiring precise values for each parameter because too many factors affect the human body. For example, if the patient took medication that can affect the ANS before the HRV test, the test results could be an error. In the present study, we excluded subjects with diseases that can affect the ANS and attempted to restrict subjects from ingesting food, tea, or coffee; cigarette smoking; and medications before HRV recording. We tried to perform the measurement of HRV in a clinical manner, with confirmed bladder filling to at least 100 mL before testing and with the subjects lying down to rest for 10 minutes with normal breathing before the test.</p><p>In a pilot study of HRV in men with LUTS, the patients with LUTS had lower HF than did men in the healthy control group, and men with predominant voiding symptoms had a higher LF/HF ratio than did men with predominant storage symptoms [<xref rid="B4" ref-type="bibr">4</xref>]. These findings indicated that an imbalance in ANS activity could be related to the cause or mechanism of the appearance of LUTS.</p><p>Because we found no normal values for identifying ANS activity with HRV parameters in Korean men, we performed a pilot study with healthy volunteers to identify the standard LF/HF ratio. We evaluated HRV in 118 healthy volunteers from a health promotion center to get values of LF/HF in men without LUTS. The men were aged between 40 and 70 years and had a total IPSS of less than 8. HRV was evaluated in the same manner as in the study protocol to get a mean of LF/HF ratio, which was found to be 1.6. We therefore defined an LF/HF of less than or equal to 1.6 as sympathetic hypoactivity and an LF/HF of greater than 1.6 as hyperactivity. We divided the subjects according to their LF/HF ratio to compare treatment efficacies and change in LF/HF after treatment with Xatral XL 10 mg for 12 weeks.</p><p>Xatral XL is a nonselective, slow-release alpha-blocker and a representative medication with acceptable safety profiles for male LUTS patients [<xref rid="B20" ref-type="bibr">20</xref><xref rid="B21" ref-type="bibr">21</xref>]. Xatral XL was significantly effective for improving the patients' symptoms and increasing Qmax in men with both a high LF/HF ratio and a low LF/HF ratio. Between the two groups, changes in total IPSS, IPSS-voiding subscore, and IPSS-storage subscore after treatment were not significantly different.</p><p>The most interesting finding was the change in the LF/HF ratio in each group. The LF/HF ratio was increased after treatment in group A, whereas it decreased in group B (<xref ref-type="fig" rid="F2">Fig. 2</xref>). After 12 weeks of treatment with Xatral XL the LF/HF ratio in the two groups merged at approximately 1.79. This suggests that balancing ANS activity may be important for improving LUTS. In other words, an imbalance in ANS activity could be a cause or mechanism in the development of LUTS.</p><p>As in previous studies, the results of our study suggest that ANS dysfunction, especially an imbalance between sympathetic and parasympathetic activity, could be implied in idiopathic overactive bladder and that a balanced ANS is very important for maintaining lower urinary tract function.</p></sec><sec sec-type="conclusions"><title>CONCLUSIONS</title><p>It is widely known that LF reflects sympathetic activity and HF reflects parasympathetic activity. We can use HRV to evaluate a patient's autonomic function, and the LF/HF ratio can be considered to be a measure of the balance of the ANS. In this study, the mean LF/HF ratio in subjects who had a high LF/HF ratio at baseline was decreased after treatment and that in men with a low LF/HF at baseline was increased. That is, the LF/HF ratios in each group merged to approximately 1.79, near the value in healthy people. This study has shown how ANS balance is important for improving LUTS and is related to treatment efficacy with alpha-blockers. This finding is a clue that an imbalance in the ANS may be a causative factor for LUTS and may influence the efficacy of treatment.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>This study was performed with funding from Handok Inc.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>CONFLICTS OF INTEREST:</bold> The authors have nothing to disclose.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ushijima</surname><given-names>S</given-names></name><name><surname>Ukimura</surname><given-names>O</given-names></name><name><surname>Okihara</surname><given-names>K</given-names></name><name><surname>Mizutani</surname><given-names>Y</given-names></name><name><surname>Kawauchi</surname><given-names>A</given-names></name><name><surname>Miki</surname><given-names>T</given-names></name></person-group><article-title>Visual analog scale questionnaire to assess quality of life specific to each symptom of the International Prostate Symptom Score</article-title><source>J Urol</source><year>2006</year><volume>176</volume><fpage>665</fpage><lpage>671</lpage><pub-id pub-id-type="pmid">16813918</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hubeaux</surname><given-names>K</given-names></name><name><surname>Deffieux</surname><given-names>X</given-names></name><name><surname>Raibaut</surname><given-names>P</given-names></name><name><surname>Le Breton</surname><given-names>F</given-names></name><name><surname>Jousse</surname><given-names>M</given-names></name><name><surname>Amarenco</surname><given-names>G</given-names></name></person-group><article-title>Evidence for autonomic nervous system dysfunction in females with idiopathic overactive bladder syndrome</article-title><source>Neurourol Urodyn</source><year>2011</year><volume>30</volume><fpage>1467</fpage><lpage>1472</lpage><pub-id pub-id-type="pmid">21717506</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>DG</given-names></name><name><surname>Cho</surname><given-names>DS</given-names></name><name><surname>Yun</surname><given-names>IS</given-names></name><name><surname>Lee</surname><given-names>KB</given-names></name><name><surname>Choi</surname><given-names>JB</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name></person-group><article-title>The difference of lower urinary tract symptoms between sympathetic hyperactive and hypoactive men</article-title><source>Int Neurourol J</source><year>2013</year><volume>17</volume><fpage>30</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">23610709</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>JB</given-names></name><name><surname>Lee</surname><given-names>JG</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name></person-group><article-title>Characteristics of autonomic nervous system activity in men with lower urinary tract symptoms (LUTS): analysis of heart rate variability in men with LUTS</article-title><source>Urology</source><year>2010</year><volume>75</volume><fpage>138</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">19854482</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SG</given-names></name><name><surname>Chung</surname><given-names>BH</given-names></name><name><surname>Lee</surname><given-names>SW</given-names></name><name><surname>Park</surname><given-names>JK</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Cheon</surname><given-names>J</given-names></name><etal/></person-group><article-title>Alpha-blocker treatment response in men with lower urinary tract symptoms based on sympathetic activity: prospective, multicenter, open-labeled, observational study</article-title><source>Int Neurourol J</source><year>2015</year><volume>19</volume><fpage>107</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">26126440</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ventura</surname><given-names>S</given-names></name><name><surname>Oliver</surname><given-names>Vl</given-names></name><name><surname>White</surname><given-names>CW</given-names></name><name><surname>Xie</surname><given-names>JH</given-names></name><name><surname>Haynes</surname><given-names>JM</given-names></name><name><surname>Exintaris</surname><given-names>B</given-names></name></person-group><article-title>Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH)</article-title><source>Br J Pharmacol</source><year>2011</year><volume>163</volume><fpage>891</fpage><lpage>907</lpage><pub-id pub-id-type="pmid">21410684</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roehrborn</surname><given-names>CG</given-names></name><name><surname>Schwinn</surname><given-names>DA</given-names></name></person-group><article-title>Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia</article-title><source>J Urol</source><year>2004</year><volume>171</volume><fpage>1029</fpage><lpage>1035</lpage><pub-id pub-id-type="pmid">14767264</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miano</surname><given-names>R</given-names></name><name><surname>De Nunzio</surname><given-names>C</given-names></name><name><surname>Asimakopoulos</surname><given-names>AD</given-names></name><name><surname>Germani</surname><given-names>S</given-names></name><name><surname>Tubaro</surname><given-names>A</given-names></name></person-group><article-title>Treatment options for benign prostatic hyperplasia in older men</article-title><source>Med Sci Monit</source><year>2008</year><volume>14</volume><fpage>RA94</fpage><lpage>R102</lpage><pub-id pub-id-type="pmid">18591930</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Low</surname><given-names>PA</given-names></name></person-group><article-title>Testing the autonomic nervous system</article-title><source>Semin Neurol</source><year>2003</year><volume>23</volume><fpage>407</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">15088262</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshimura</surname><given-names>N</given-names></name><name><surname>Ogawa</surname><given-names>T</given-names></name><name><surname>Miyazato</surname><given-names>M</given-names></name><name><surname>Kitta</surname><given-names>T</given-names></name><name><surname>Furuta</surname><given-names>A</given-names></name><name><surname>Chancellor</surname><given-names>MB</given-names></name><etal/></person-group><article-title>Neural mechanisms underlying lower urinary tract dysfunction</article-title><source>Korean J Urol</source><year>2014</year><volume>55</volume><fpage>81</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">24578802</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazur</surname><given-names>DJ</given-names></name><name><surname>Helfand</surname><given-names>BT</given-names></name><name><surname>McVary</surname><given-names>KT</given-names></name></person-group><article-title>Influences of neuroregulatory factors on the development of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction in aging men</article-title><source>Urol Clin North Am</source><year>2012</year><volume>39</volume><fpage>77</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">22118347</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McVary</surname><given-names>KT</given-names></name><name><surname>Razzaq</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Venegas</surname><given-names>MF</given-names></name><name><surname>Rademaker</surname><given-names>A</given-names></name><name><surname>McKenna</surname><given-names>KE</given-names></name></person-group><article-title>Growth of the rat prostate gland is facilitated by the autonomic nervous system</article-title><source>Biol Reprod</source><year>1994</year><volume>51</volume><fpage>99</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">7918880</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McVary</surname><given-names>KT</given-names></name><name><surname>Rademaker</surname><given-names>A</given-names></name><name><surname>Lloyd</surname><given-names>GL</given-names></name><name><surname>Gann</surname><given-names>P</given-names></name></person-group><article-title>Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia</article-title><source>J Urol</source><year>2005</year><volume>174</volume><fpage>1327</fpage><lpage>1433</lpage><pub-id pub-id-type="pmid">16145413</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massin</surname><given-names>MM</given-names></name><name><surname>Derkenne</surname><given-names>B</given-names></name><name><surname>von Bernuth</surname><given-names>G</given-names></name></person-group><article-title>Correlations between indices of heart rate variability in healthy children and children with congenital heart disease</article-title><source>Cardiology</source><year>1999</year><volume>91</volume><fpage>109</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">10449882</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bigger</surname><given-names>JT</given-names><suffix>Jr</suffix></name><name><surname>Fleiss</surname><given-names>JL</given-names></name><name><surname>Steinman</surname><given-names>RC</given-names></name><name><surname>Rolnitzky</surname><given-names>LM</given-names></name><name><surname>Kleiger</surname><given-names>RE</given-names></name><name><surname>Rottman</surname><given-names>JN</given-names></name></person-group><article-title>Frequency domain measures of heart period variability and mortality after myocardial infarction</article-title><source>Circulation</source><year>1992</year><volume>85</volume><fpage>164</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">1728446</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akselrod</surname><given-names>S</given-names></name><name><surname>Gordon</surname><given-names>D</given-names></name><name><surname>Ubel</surname><given-names>FA</given-names></name><name><surname>Shannon</surname><given-names>DC</given-names></name><name><surname>Berger</surname><given-names>AC</given-names></name><name><surname>Cohen</surname><given-names>RJ</given-names></name></person-group><article-title>Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control</article-title><source>Science</source><year>1981</year><volume>213</volume><fpage>220</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">6166045</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malliani</surname><given-names>A</given-names></name><name><surname>Pagani</surname><given-names>M</given-names></name><name><surname>Lombardi</surname><given-names>F</given-names></name><name><surname>Cerutti</surname><given-names>S</given-names></name></person-group><article-title>Cardiovascular neural regulation explored in the frequency domain</article-title><source>Circulation</source><year>1991</year><volume>84</volume><fpage>482</fpage><lpage>492</lpage><pub-id pub-id-type="pmid">1860193</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Appel</surname><given-names>ML</given-names></name><name><surname>Berger</surname><given-names>RD</given-names></name><name><surname>Saul</surname><given-names>JP</given-names></name><name><surname>Smith</surname><given-names>JM</given-names></name><name><surname>Cohen</surname><given-names>RJ</given-names></name></person-group><article-title>Beat to beat variability in cardiovascular variables: noise or music</article-title><source>J Am Coll Cardiol</source><year>1989</year><volume>14</volume><fpage>1139</fpage><lpage>1148</lpage><pub-id pub-id-type="pmid">2681319</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><collab>Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology</collab><article-title>Heart rate variability. Standards of measurement, physiological interpretation, and clinical use</article-title><source>Eur Heart J</source><year>1996</year><volume>17</volume><fpage>354</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">8737210</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roehrborn</surname><given-names>CG</given-names></name><name><surname>Van Kerrebroeck</surname><given-names>P</given-names></name><name><surname>Nordling</surname><given-names>J</given-names></name></person-group><article-title>Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies</article-title><source>BJU Int</source><year>2003</year><volume>92</volume><fpage>257</fpage><lpage>261</lpage><pub-id pub-id-type="pmid">12887479</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeo</surname><given-names>JK</given-names></name><name><surname>Choi</surname><given-names>H</given-names></name><name><surname>Bae</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Yang</surname><given-names>SO</given-names></name><name><surname>Oh</surname><given-names>CY</given-names></name><etal/></person-group><article-title>Korean clinical practice guideline for benign prostatic hyperplasia</article-title><source>Investig Clin Urol</source><year>2016</year><volume>57</volume><fpage>30</fpage><lpage>44</lpage></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Fig. 1</label><caption><title>Patient disposition and enrollment. HRV, heart rate variability; LF, low frequency; HF, high frequency.</title></caption><graphic xlink:href="icu-59-49-g001"/></fig><fig id="F2" orientation="portrait" position="float"><label>Fig. 2</label><caption><title>Change in low frequency (LF)/high frequency (HF) ratio after
treatment with Xatral XL (group A: LF/HF &#x02264;1.6, group B: LF/HF &#x0003e;1.6).</title></caption><graphic xlink:href="icu-59-49-g002"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Characteristics of the subjects at baseline</title></caption><alternatives><graphic xlink:href="icu-59-49-i001"/><table frame="hsides" rules="rows"><col width="31.66%" span="1"/><col width="25.74%" span="1"/><col width="24.26%" span="1"/><col width="18.34%" span="1"/><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(217,220,235)">Characteristic</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(217,220,235)">Group A (n=54)</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(217,220,235)">Group B (n=41)</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(217,220,235)">p-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (y)</td><td valign="top" align="center" rowspan="1" colspan="1">65.5&#x000b1;7.68</td><td valign="top" align="center" rowspan="1" colspan="1">62.7&#x000b1;5.75</td><td valign="top" align="center" rowspan="1" colspan="1">0.055</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LF (ms<sup>2</sup>)</td><td valign="top" align="center" rowspan="1" colspan="1">104.5&#x000b1;128.22</td><td valign="top" align="center" rowspan="1" colspan="1">132.9&#x000b1;105.95</td><td valign="top" align="center" rowspan="1" colspan="1">0.253</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HF (ms<sup>2</sup>)</td><td valign="top" align="center" rowspan="1" colspan="1">137.7&#x000b1;216.28</td><td valign="top" align="center" rowspan="1" colspan="1">47.8&#x000b1;43.64</td><td valign="top" align="center" rowspan="1" colspan="1">0.010</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LF/HF</td><td valign="top" align="center" rowspan="1" colspan="1">0.89&#x000b1;0.407</td><td valign="top" align="center" rowspan="1" colspan="1">3.93&#x000b1;5.471</td><td valign="top" align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total IPSS</td><td valign="top" align="center" rowspan="1" colspan="1">15.8&#x000b1;5.68</td><td valign="top" align="center" rowspan="1" colspan="1">15.7&#x000b1;5.60</td><td valign="top" align="center" rowspan="1" colspan="1">0.936</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IPSS-voiding subscore</td><td valign="top" align="center" rowspan="1" colspan="1">9.9&#x000b1;4.89</td><td valign="top" align="center" rowspan="1" colspan="1">9.4&#x000b1;3.82</td><td valign="top" align="center" rowspan="1" colspan="1">0.622</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IPSS-storage subscore</td><td valign="top" align="center" rowspan="1" colspan="1">5.9&#x000b1;2.90</td><td valign="top" align="center" rowspan="1" colspan="1">6.2&#x000b1;3.00</td><td valign="top" align="center" rowspan="1" colspan="1">0.582</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Qmax (mL/s)</td><td valign="top" align="center" rowspan="1" colspan="1">10.3&#x000b1;4.17</td><td valign="top" align="center" rowspan="1" colspan="1">9.4&#x000b1;4.00</td><td valign="top" align="center" rowspan="1" colspan="1">0.297</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Values are presented as mean&#x000b1;standard deviation.</p><p>Group A, LF/HF &#x02264;1.6; group B, LF/HF &#x0003e;1.6; LF, low frequency; HF, high frequency; IPSS, International Prostate Symptom Score; Qmax, maximal uroflow.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Change in mean total IPSS, IPSS subscores, Qmax, and LF/HF ratio after treatment with Xatral XL 10 mg for 12 weeks</title></caption><alternatives><graphic xlink:href="icu-59-49-i002"/><table frame="hsides" rules="rows"><col width="27.35%" span="1"/><col width="16.09%" span="1"/><col width="18.23%" span="1"/><col width="16.09%" span="1"/><col width="22.25%" span="1"/><thead><tr><th valign="middle" align="left" rowspan="2" colspan="1" style="background-color:rgb(217,220,235)">Parameter</th><th valign="middle" align="center" rowspan="1" colspan="2" style="background-color:rgb(217,220,235)">Group A</th><th valign="middle" align="center" rowspan="1" colspan="2" style="background-color:rgb(217,220,235)">Group B</th></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(217,220,235)">Baseline</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(217,220,235)">12 weeks</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(217,220,235)">Baseline</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(217,220,235)">12 weeks</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Total IPSS</td><td valign="top" align="center" rowspan="1" colspan="1">15.7&#x000b1;5.62</td><td valign="top" align="center" rowspan="1" colspan="1">10.9&#x000b1;6.13<sup>a</sup></td><td valign="top" align="center" rowspan="1" colspan="1">15.8&#x000b1;5.68</td><td valign="top" align="center" rowspan="1" colspan="1">10.1&#x000b1;6.11<sup>a</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IPSS-voiding subscore</td><td valign="top" align="center" rowspan="1" colspan="1">9.7&#x000b1;4.20</td><td valign="top" align="center" rowspan="1" colspan="1">6.4&#x000b1;4.11<sup>a</sup></td><td valign="top" align="center" rowspan="1" colspan="1">9.9&#x000b1;4.49</td><td valign="top" align="center" rowspan="1" colspan="1">6.0&#x000b1;4.35<sup>a</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IPSS-storage subscore</td><td valign="top" align="center" rowspan="1" colspan="1">6.1&#x000b1;2.93</td><td valign="top" align="center" rowspan="1" colspan="1">4.6&#x000b1;2.75<sup>a</sup></td><td valign="top" align="center" rowspan="1" colspan="1">5.9&#x000b1;2.90</td><td valign="top" align="center" rowspan="1" colspan="1">4.1&#x000b1;2.56<sup>a</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Qmax (mL/s)</td><td valign="top" align="center" rowspan="1" colspan="1">10.3&#x000b1;4.17</td><td valign="top" align="center" rowspan="1" colspan="1">15.7&#x000b1;8.00<sup>a</sup></td><td valign="top" align="center" rowspan="1" colspan="1">9.31&#x000b1;3.99</td><td valign="top" align="center" rowspan="1" colspan="1">14.0&#x000b1;7.94<sup>a</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LF (ms<sup>2</sup>)</td><td valign="top" align="center" rowspan="1" colspan="1">104.5&#x000b1;128.22</td><td valign="top" align="center" rowspan="1" colspan="1">197.4&#x000b1;452.48<sup>a</sup></td><td valign="top" align="center" rowspan="1" colspan="1">132.9&#x000b1;105.95</td><td valign="top" align="center" rowspan="1" colspan="1">209.0&#x000b1;343.34<sup>a</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HF (ms<sup>2</sup>)</td><td valign="top" align="center" rowspan="1" colspan="1">137.7&#x000b1;216.28</td><td valign="top" align="center" rowspan="1" colspan="1">138.98&#x000b1;175.81</td><td valign="top" align="center" rowspan="1" colspan="1">47.8&#x000b1;43.64</td><td valign="top" align="center" rowspan="1" colspan="1">161.6&#x000b1;175.81<sup>a</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LF/HFb</td><td valign="top" align="center" rowspan="1" colspan="1">0.89&#x000b1;0.407</td><td valign="top" align="center" rowspan="1" colspan="1">1.80&#x000b1;1.804<sup>a</sup></td><td valign="top" align="center" rowspan="1" colspan="1">3.93&#x000b1;5.471</td><td valign="top" align="center" rowspan="1" colspan="1">1.79&#x000b1;1.153<sup>a</sup></td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>Values are presented as mean&#x000b1;standard deviation.</p><p>IPSS, International Prostate Symptom Score; Qmax, maximal uroflow; LF, low frequency; HF, high frequency; group A, LF/HF &#x02264;1.6; group B, LF/HF &#x0003e;1.6.</p><p><sup>a</sup>:Difference from baseline, p&#x0003c;0.05. <sup>b</sup>:Difference between groups, p&#x0003c;0.05.</p></fn></table-wrap-foot></table-wrap></floats-group></article>